Dr. Sammita Satyanarayan, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 65
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 304018
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
- Mount Sinai Beth Israel New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 65
- Services billed
- 154
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in New York, NY | 33 |
| Baclofen Other prescribers in New York, NY | 32 |
| Tecfidera (dimethyl fumarate) | 21 |
| Dalfampridine Er (dalfampridine) | 14 |
| Glatiramer Acetate | 13 |
| Dimethyl Fumarate | 12 |
| Tizanidine Hcl Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,700 in total to this clinician.
| Tg Therapeutics, Inc. | $2,700 |
|---|
| Consulting Fee | $2,700 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tg Therapeutics, Inc. May 23, 2025 | Consulting Fee BRIUMVI · Immunology | $2,700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $72,693 in research payments for these studies, mostly to the institutions running them.
- Impact of structured wellness intervention on quality of life in NMOSD
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.